drugset / Trial / NCT00459615
Phase II Dose Ranging Study of Artesunate
Phase 2
Completed
120 enrolled
U.S. Army Office of the Surgeon General
Military Infectious Diseases Research Program (MIDRP) · collabU.S. Army Medical Research and Development Command · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to compare four regimens using US FDA GMP intravenous artesunate for the treatment of uncomplicated Plasmodium falciparum malaria to identify the most effective treatment regimen as determined by rapidity of parasite clearance by microscopy.
Timeline
- Start
- 2007-04
- Primary completion
- 2007-12
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artesunate | Small molecule | 2.4 mg/kg | Intravenous |